Steady Expansion Forecast for Transmucosal Drug Delivery Devices Market, Projected to Reach $78.21 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Transmucosal Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for transmucosal drug delivery devices has seen a significant increase in size over the recent years. It is projected to expand from a value of $50.24 billion in 2024 to $55.04 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. The historical growth of this market has been driven by the demand for quick relief from angina, the efficiency of sublingual administration for swift absorption into the bloodstream, the aim to circumnavigate gastrointestinal degradation, the invention of buccal tablets, and the necessity for non-intrusive delivery methods for peptides and proteins.

Transmucosal Drug Delivery Devices Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, the market for transmucosal drug delivery devices is predicted to witness robust growth. The market valuation is projected to climb to $78.21 billion by 2029, with a compound annual growth rate (CAGR) of 9.2%. A variety of factors contribute to this predicted growth, including the advent of intelligent drug delivery systems, a rise in the number of chronic disease sufferers, an emphasis on bespoke medicine, an aging populace with increased medication demands, and a greater level of consciousness. The period of forecast is expected to see major trends such as the expansion in the scope of therapeutic applications, personalization of drug delivery devices, regulatory affirmations, and evolving markets, alongside eco-friendly devices and groundbreaking formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report

What Are the Drivers Transforming the Transmucosal Drug Delivery Devices Market?
The escalating incidence of chronic ailments is anticipated to drive the progression of the transmucosal drug delivery devices sector in the future. A chronic illness is a condition that typically develops over a long period and persists, often necessitating continued medical intervention to manage symptoms and avert potential complications. The increasing occurrence of chronic diseases can be attributed to factors like lifestyle, ageing demographics, environmental issues, healthcare system dilemmas, and urbanization. Transmucosal drug delivery apparatus is employed in handling chronic diseases to ensure an effective, regulated delivery of medication, maintaining therapeutic levels for managing symptoms and enhancing patient compliance. For instance, the Leukemia & Lymphoma Society (LLS), a charity organization based in the US, released a report in August 2023 indicating that in the US, someone is diagnosed with leukemia, lymphoma, or myeloma every three minutes. Expectedly, in 2023, around 184,720 individuals should receive these diagnoses, accounting for 9.4% of the projected 1,958,310 new cancer incidences for the year. Consequently, the escalating incidence of chronic diseases is propelling the transmucosal drug delivery devices sector forward.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp

What Long-Term Trends Will Define the Future of the Transmucosal Drug Delivery Devices Market?
Leading corporations in the transmucosal drug delivery device market are propelling innovation with smart platforms, including proprietary transdermal patch delivery platforms, to boost drug absorption and augment patient comfort and adherence. These proprietary transdermal patch delivery platforms are unique technological tools owned by corporations, designed to administer medications through the skin for a controlled release and improved therapeutic results. For instance, Starton Therapeutics Inc., a biotechnology company based in the U.S, introduced STARSILON in January 2024, a proprietary transdermal patch delivery platform with extended utility, targeting the therapeutic delivery of complex-to-develop APIs. This broadens the scope of transdermal drug delivery for complex active pharmaceutical ingredients (APIs), thereby increasing therapeutic effectiveness through sustained delivery rates.

Which Segments in the Transmucosal Drug Delivery Devices Market Offer the Most Profit Potential?
The transmucosal drug delivery devices market covered in this report is segmented -

1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals

Subsegments:
1) By Passive Transdermal Drug Delivery: Reservoir Systems, Matrix Systems, Micro-Needle Systems, Pressure-Sensitive Adhesive Systems
2) By Active Transdermal Drug Delivery: Iontophoresis, Sonophoresis, Electroporation, Thermal Ablation, Microporation

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16812&type=smp

Which Firms Dominate the Transmucosal Drug Delivery Devices Market by Market Share and Revenue in 2025?
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.

Which Regions Offer the Highest Growth Potential in the Transmucosal Drug Delivery Devices Market?
North America was the largest region in the transmucosal drug delivery devices market in 2024. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16812

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.